Matrix Partners China
VC Fund
Beijing, China
Matrix Partners China is a VC fund in Beijing focused on Health Care and Software. Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
- Total investments:
- 667
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $92M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Matrix Partners China invests in
Stages Matrix Partners China invests in
Countries Matrix Partners China invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 16 contacts → | |||
Round size
- Seed
- $1.5M–$74M
- Series A
- $2.9M–$56M
- Series B
- $10M–$141M
Investment Focus
Industry
- Health Care 59 (9%)
- Software 53 (8%)
- Biotechnology 45 (7%)
- Artificial Intelligence 45 (7%)
- Information Technology 44 (7%)
Stage
- Series A 205 (31%)
- Series B 152 (23%)
- Seed 76 (11%)
- Series C 60 (9%)
- Angel 52 (8%)
Country
- China 392 (59%)
- United States 33 (5%)
- Singapore 7 (1%)
- Hong Kong 5 (1%)
- India 2 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Zhang
Managing Partner / Co Founder
|
Managing Partner / Co Founder | Total investments: 1 | Find email | |
Eric YU
Partner, Head of Healthcare
|
Partner, Head of Healthcare | Total investments: 8 | Find email | |
Guoxiong Cao
Partner (RMB Funds)
|
Partner (RMB Funds) | Total investments: 1 | Find email | |
Kevin Xiong
Partner
|
Partner | Total investments: 2 | Find email | |
Mi Zhou
Director
|
Director | Total investments: 0 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Inna New Energy
|
Yingna New Energy is a technology-based enterprise focusing on the R&D and production of cathode materials for sodium-ion batteries. | Series A / Sep 15, 2026 | |
| Shanghai Zongwei Automation Co., Ltd. (ZONGWEI) is a research and development enterprise focusing on automation flexibility technology and solutions. The company has leading linear motion control core technology and experience, and independently developed key supporting equipment such as controllers, driver series and feedback systems dedicated tolinear motion. High-performance products and super-optimal solutions have been widely used in semiconductors, new energy, high-end daily chemicals, 3C electronics and other fields, improving delivery efficiency and reducing production costs for many world-class industrial giants and listed company customers. | $29.8M / Series C / Sep 09, 2026 | ||
Xingyue Semiconductor
|
Xingyue Semiconductor designs, develops, and distributes integrated circuits and devices. | $149M / Series B / Sep 04, 2026 | |
| NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. | $80M / Series B / Sep 03, 2026 | ||
Tiangong Robotics
|
Tiangong Robotics is a high-tech pioneer in the warehouse automation sector. It is recognised as the creator and industry leader of the 3D Sorter. | Seed / Sep 02, 2026 | |
VAST
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $446.4M / Series B / Sep 01, 2026 | |
Convergen
|
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates | $15M / Seed / Aug 31, 2026 | |
| Miwei Technology focuses on the research and development of service-oriented intelligent computing systems, forming a product system centered on intelligent computing operating system + intelligent edge computing + intelligent cloud computing. | $14.9M / Series A / Aug 31, 2026 | ||
|
Xijian Technology
|
XiJian Technology operates an intellectual property and commercialization pipeline for neuromorphic perception technology by implementing its proprietary "Tianmou" vision chip paradigm. Its architectural design mimics human retinal pathways by extracting discrete visual primitives at the hardware level to circumvent bandwidth constraintsin computational processing. This hardware-software approach provides an ultra-low latency, high dynamic range input layer tailored specifically for foundational world models and downstream physical robotic agents. | $74.4M / Seed / Aug 26, 2026 | |
|
CaiKeYuanTu
|
CaiKeYuanTu is an AI-powered materials modeling platform that leverages advanced machine learning algorithms to simulate, predict, and optimize the properties and behaviors of new materials with high accuracy and efficiency. | Angel / Aug 21, 2026 | |
| See all 667 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Matrix Partners China invest in?
Matrix Partners China invests primarily in Health Care, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 667 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Matrix Partners China's check size?
Matrix Partners China typically joins rounds of $1.5M–$74M at Seed, $2.9M–$56M at Series A and $10M–$141M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Matrix Partners China participates in.
How do I contact Matrix Partners China?
Public channels for Matrix Partners China include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Matrix Partners China?
The team at Matrix Partners China includes David Zhang (Managing Partner / Co Founder), Eric YU (Partner, Head of Healthcare) and Guoxiong Cao (Partner (RMB Funds)), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
